APRI vs. BNTC, AGE, TNXP, MNPR, ABVC, IMNN, MIRA, ERNA, RDHL, and NNVC
Should you be buying Apricus Biosciences stock or one of its competitors? The main competitors of Apricus Biosciences include Benitec Biopharma (BNTC), AgeX Therapeutics (AGE), Tonix Pharmaceuticals (TNXP), Monopar Therapeutics (MNPR), ABVC BioPharma (ABVC), Imunon (IMNN), MIRA Pharmaceuticals (MIRA), Eterna Therapeutics (ERNA), RedHill Biopharma (RDHL), and NanoViricides (NNVC). These companies are all part of the "medical" sector.
Apricus Biosciences (NASDAQ:APRI) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.
Apricus Biosciences has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.
Apricus Biosciences received 49 more outperform votes than Benitec Biopharma when rated by MarketBeat users. Likewise, 69.91% of users gave Apricus Biosciences an outperform vote while only 63.73% of users gave Benitec Biopharma an outperform vote.
In the previous week, Benitec Biopharma had 10 more articles in the media than Apricus Biosciences. MarketBeat recorded 10 mentions for Benitec Biopharma and 0 mentions for Apricus Biosciences. Benitec Biopharma's average media sentiment score of 0.21 beat Apricus Biosciences' score of 0.00 indicating that Benitec Biopharma is being referred to more favorably in the news media.
Benitec Biopharma has a consensus target price of $16.00, indicating a potential upside of 133.24%. Given Benitec Biopharma's higher possible upside, analysts plainly believe Benitec Biopharma is more favorable than Apricus Biosciences.
19.9% of Apricus Biosciences shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 2.3% of Apricus Biosciences shares are owned by company insiders. Comparatively, 4.3% of Benitec Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Benitec Biopharma's return on equity of -204.34% beat Apricus Biosciences' return on equity.
Apricus Biosciences has higher revenue and earnings than Benitec Biopharma.
Summary
Benitec Biopharma beats Apricus Biosciences on 9 of the 14 factors compared between the two stocks.
Get Apricus Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APRI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apricus Biosciences Competitors List
Related Companies and Tools
